Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK Cidra Manufacturing FDA-483 Reports Cite Ariflo, 12 Other Products

Executive Summary

GlaxoSmithKline's pending chronic obstructive pulmonary disease therapy Ariflo (cilomilast) is among a dozen products manufactured in Cidra, Puerto Rico cited in recent FDA "Form 483" reports

You may also be interested in...



Alcon To Try Glaxo’s Ariflo For Dry Eye

Swiss firm builds pipeline with help from GSK and Origenis in latest eye care in-licensing deals.

Avandaryl Approval On Track Despite Consent Decree, GSK Says

GlaxoSmithKline is confident FDA will approve its diabetes line extension agent Avandaryl on schedule despite the fact that the manufacturing facility for the product is operating under a GMP consent decree

Avandaryl Approval On Track Despite Consent Decree, GSK Says

GlaxoSmithKline is confident FDA will approve its diabetes line extension agent Avandaryl on schedule despite the fact that the manufacturing facility for the product is operating under a GMP consent decree

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS045535

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel